RxDoctor Payments Data

Irina Shchepina, APRN

Acute Care · Jupiter, FLNPI 1427757236

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,654 of the $5,740 with a category attached, or 81.1%. 20 manufacturers reported payments, led by Boston Scientific at 27.2% of the total. Among acute care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,740in general payments, 2019–2025

Across 174 payments — averaging $32.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Johnson & Johnson$772
  • Boehringer Ingelheim$664
  • Amgen$596
  • Novartis$372
  • Medtronic$356
  • plus $1K from 14 others

What the payments were for

  • Travel & lodging$1,08619%
  • Food & beverage$4,65481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,740 in reported general payments places this provider in the 95th percentile of 1,150 acute care providers in Florida.

See all acute care providers in Florida

Medicare billing

Part B allowed, 2024
$6,580
Medicare patients
30
Services billed
59

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban91$125,032
XareltoRivaroxaban33$37,674
EntrestoSacubitril/Valsartan21$26,705
JardianceEmpagliflozin19$23,219
Ranolazine ErRanolazine11$1,164
Metoprolol Succinate84$1,051
Losartan Potassium86$908
Midodrine Hcl11$577
Rosuvastatin Calcium45$422
Valsartan12$362
ClopidogrelClopidogrel Bisulfate31$316
Atorvastatin Calcium31$296
Carvedilol12$245
Metoprolol Tartrate53$239
Lisinopril26$223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$59$125,03291 claims
Johnson & JohnsonXarelto$772$37,67433 claims
NovartisEntresto$372$26,70521 claims
Boehringer IngelheimJardiance$664$23,21919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,150 acute care providers in Florida.

Other acute care in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →